RU2011106331A - ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА - Google Patents
ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА Download PDFInfo
- Publication number
- RU2011106331A RU2011106331A RU2011106331/04A RU2011106331A RU2011106331A RU 2011106331 A RU2011106331 A RU 2011106331A RU 2011106331/04 A RU2011106331/04 A RU 2011106331/04A RU 2011106331 A RU2011106331 A RU 2011106331A RU 2011106331 A RU2011106331 A RU 2011106331A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- methyl
- day
- pharmaceutically acceptable
- body weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение формулы I ! ! или его фармацевтически приемлемая соль, где R1 представляет собой С1-4 алкил, необязательно замещенный гидроксигруппой. ! 2. Соединение по п.1, в котором R1 представляет собой метил. ! 3. Соединение по п.1, в котором R1 представляет собой этил или циклобутил. ! 4. Соединение по п.1, которое представляет собой N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамид, или его фармацевтически приемлемой соли. ! 5. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель. ! 6. Способ лечения аллергических реакций, аллергического дерматита, атопического дерматита, экземы или зуда у млекопитающих, включающий введение нуждающемуся млекопитающему терапевтически эффективного количества соединения по п.1. ! 7. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,01 мг/кг веса тела/день до 100 мг/кг веса тела/день. ! 8. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,1 мг/кг веса тела/день до 10 мг/кг веса тела/день. ! 9. Способ по п.6, в котором млекопитающее включает животных-компаньонов. ! 10. Способ по п.9, в котором животными-компаньонами являются собаки. ! 11. Способ по п.6, в котором млекопитающее включает домашний скот. ! 12. Способ по п.6, в котором соединение по п.1 вводят перорально, парентерально или местно. ! 13. Способ лечения нейродегенеративных заболеваний, кератоконъюнктивита, хронических респираторных заболеваний, аутоиммунных заболеваний, воспалительного заболевания кишечника, неоплазии, артритных состояний, рака, лейкемии, волчанки и множественн
Claims (18)
2. Соединение по п.1, в котором R1 представляет собой метил.
3. Соединение по п.1, в котором R1 представляет собой этил или циклобутил.
4. Соединение по п.1, которое представляет собой N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамид, или его фармацевтически приемлемой соли.
5. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
6. Способ лечения аллергических реакций, аллергического дерматита, атопического дерматита, экземы или зуда у млекопитающих, включающий введение нуждающемуся млекопитающему терапевтически эффективного количества соединения по п.1.
7. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,01 мг/кг веса тела/день до 100 мг/кг веса тела/день.
8. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,1 мг/кг веса тела/день до 10 мг/кг веса тела/день.
9. Способ по п.6, в котором млекопитающее включает животных-компаньонов.
10. Способ по п.9, в котором животными-компаньонами являются собаки.
11. Способ по п.6, в котором млекопитающее включает домашний скот.
12. Способ по п.6, в котором соединение по п.1 вводят перорально, парентерально или местно.
13. Способ лечения нейродегенеративных заболеваний, кератоконъюнктивита, хронических респираторных заболеваний, аутоиммунных заболеваний, воспалительного заболевания кишечника, неоплазии, артритных состояний, рака, лейкемии, волчанки и множественной миеломы у млекопитающего, включающий введение нуждающемуся в этом млекопитающему терапевтически эффективного количества соединения по п.1.
14. Кристаллическая Форма А соли N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой.
15. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,2, 12,6 и 15,7.
16. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,2, 12,6, 15,7, 18,5, 27 и 28,38.
17. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,178, 8,519, 12,601, 13,819, 15,478, 15,719, 16,32, 17,997, 18,539, 20,298, 20,659, 21,583, 22,642, 23,08, 24,86, 25,602, 26,582, 27,02, 27,721, 28,161, 28,38.
18. Способ получения Формы А соли N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой, включающий взаимодействие N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9037108P | 2008-08-20 | 2008-08-20 | |
US61/090,371 | 2008-08-20 | ||
PCT/IB2009/053514 WO2010020905A1 (en) | 2008-08-20 | 2009-08-10 | Pyrrolo[2,3-d]pyrimidine compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011106331A true RU2011106331A (ru) | 2012-08-27 |
RU2493157C2 RU2493157C2 (ru) | 2013-09-20 |
Family
ID=41259411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011106331/04A RU2493157C2 (ru) | 2008-08-20 | 2009-08-10 | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
Country Status (27)
Country | Link |
---|---|
US (4) | US8133899B2 (ru) |
EP (1) | EP2384326B1 (ru) |
JP (1) | JP4884570B2 (ru) |
KR (1) | KR101335843B1 (ru) |
CN (1) | CN102131812B (ru) |
AR (2) | AR073073A1 (ru) |
AU (1) | AU2009283844B2 (ru) |
BR (1) | BRPI0917459B1 (ru) |
CA (1) | CA2733359C (ru) |
CL (1) | CL2011000353A1 (ru) |
CO (1) | CO6331437A2 (ru) |
DK (1) | DK2384326T3 (ru) |
EC (1) | ECSP11010904A (ru) |
ES (1) | ES2467109T3 (ru) |
HK (1) | HK1160116A1 (ru) |
HR (1) | HRP20140395T1 (ru) |
ME (1) | ME01269B (ru) |
MX (1) | MX2011001904A (ru) |
NZ (1) | NZ605292A (ru) |
PL (1) | PL2384326T3 (ru) |
PT (1) | PT2384326E (ru) |
RS (1) | RS53382B (ru) |
RU (1) | RU2493157C2 (ru) |
SI (1) | SI2384326T1 (ru) |
UY (1) | UY32059A (ru) |
WO (1) | WO2010020905A1 (ru) |
ZA (1) | ZA201101701B (ru) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2426129T3 (pl) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
ME00960B (me) | 2007-06-13 | 2012-06-20 | Incyte Corp | Soli inhibitora janus kinaze, (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila |
JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
LT2432472T (lt) | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AP2012006192A0 (en) * | 2009-10-15 | 2012-04-30 | Pfizer | PyrroloÄ2,3-DÜ pyrimidine compounds. |
MA33975B1 (fr) | 2009-11-06 | 2013-02-01 | Plexxikon Inc | Composés et méthodes de modulation des kinases et leurs indications d'emploi |
CA2782720A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
CA2788659C (en) * | 2010-02-24 | 2015-05-05 | Pfizer Inc. | Veterinary compositions |
PL3050882T3 (pl) | 2010-03-10 | 2018-08-31 | Incyte Holdings Corporation | Piperydyn-4-ylowe pochodne azetydyny jako inhibitory JAK1 |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
BR112012029653B1 (pt) | 2010-05-21 | 2021-01-12 | Incyte Holdings Corporation | formulação farmacêutica para aplicação tópica em pele e seu uso |
CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2012142160A1 (en) * | 2011-04-12 | 2012-10-18 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
NZ703129A (en) * | 2012-07-17 | 2017-06-30 | Glaxosmithkline Intellectual Property (No 2) Ltd | Indolecarbonitriles as selective androgen receptor modulators |
US9522151B2 (en) | 2012-07-20 | 2016-12-20 | Zoetis Services Llc | Dosing regimen for Janus Kinase (JAK) inhibitors |
HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
ME03301B (me) | 2013-02-22 | 2019-07-20 | Pfizer | Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак) |
BR112015021458B1 (pt) | 2013-03-06 | 2022-06-07 | Incyte Holdings Corporation | "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
EP2924026A1 (en) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
UA118149C2 (uk) * | 2015-01-20 | 2018-11-26 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор jak |
PL3290418T3 (pl) | 2015-04-29 | 2019-11-29 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibitory kinaz janusowych (jak) |
UA118822C2 (uk) | 2015-05-29 | 2019-03-11 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор янус-кінази |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
EP3411355B1 (en) * | 2016-02-05 | 2020-10-28 | Siegfried AG | Process for the preparation of trans-4-amino-1-cyclohexanecarboxylic acid |
NZ744341A (en) * | 2016-02-16 | 2019-06-28 | Zoetis Services Llc | Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds |
CN107365312B (zh) * | 2016-05-13 | 2021-10-01 | 瑞博(杭州)医药科技有限公司 | 一种制备Oclacitinib的新方法 |
AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
EP3609899A1 (en) | 2017-05-23 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Glucuronide prodrugs of janus kinase inhibitors |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
TWI797242B (zh) | 2018-01-30 | 2023-04-01 | 美商英塞特公司 | 製備jak抑制劑之方法及中間物 |
BR112020017703A2 (pt) | 2018-03-16 | 2021-03-09 | Zoetis Services Llc | Anticorpos monoclonais de interleucina-31 para uso veterinário |
EP3765069A1 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptide vaccines against interleukin-31 |
SG11202009441PA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
AU2019375412A1 (en) * | 2018-11-05 | 2021-06-03 | Avista Pharma Solutions, Inc. | Chemical compounds |
NL2022471B1 (en) * | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
BR112021014525A8 (pt) * | 2019-01-30 | 2022-11-22 | Gargamel Zhuhai Biotech Ltd | Inibidor de jak e método de preparação do mesmo |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
US20230295289A1 (en) | 2019-12-20 | 2023-09-21 | Intervet Inc. | Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic Dermatitis |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN112279854B (zh) * | 2020-08-25 | 2022-04-05 | 常州齐晖药业有限公司 | 一种7H-吡咯并[2,3-d]嘧啶化合物的制备方法 |
EP4229084A1 (en) | 2020-10-15 | 2023-08-23 | Intervet International B.V. | Caninized rat antibodies to canine interleukin-31 receptor alpha |
CA3201608A1 (en) | 2020-12-18 | 2022-06-23 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
EP4294462A1 (en) | 2021-02-22 | 2023-12-27 | Zoetis Services LLC | Horse il-31 induced pruritus model |
CA3227725A1 (en) | 2021-08-20 | 2023-02-23 | Mohamad Morsey | Homodimer fusion proteins for treating atopic dermatitis |
WO2023111128A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha ii |
KR20240124925A (ko) | 2021-12-24 | 2024-08-19 | 인터벳 인터내셔널 비.브이. | 아미노피라졸 화합물의 용도 |
CN114605420B (zh) * | 2022-04-25 | 2024-07-12 | 江苏慧聚药业股份有限公司 | 马来酸奥拉替尼的合成方法 |
CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫(珠海)生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037980A (en) * | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
GB915304A (en) | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives |
US3670079A (en) * | 1970-10-06 | 1972-06-13 | Merck & Co Inc | Anabolic agents |
US4997936A (en) * | 1977-10-19 | 1991-03-05 | Merck & Co., Inc. | 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids |
US4456464A (en) * | 1982-05-19 | 1984-06-26 | Zoecon Corporation | Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control |
US4526608A (en) * | 1982-07-14 | 1985-07-02 | Zoecon Corporation | Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use |
US4590282A (en) * | 1984-09-24 | 1986-05-20 | Sandoz Ltd. | Pest control agents |
US4933339A (en) * | 1985-08-21 | 1990-06-12 | Rohm And Haas Company | (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity |
CA1328333C (en) * | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
NO169490C (no) | 1988-03-24 | 1992-07-01 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater |
US4879309A (en) * | 1988-09-27 | 1989-11-07 | Schering Corporation | Mercapto-acylamino acids as antihypertensives |
JP2983254B2 (ja) * | 1989-06-14 | 1999-11-29 | 武田薬品工業株式会社 | ピロロ〔2,3―d〕ピリミジン誘導体の製造法およびその中間体 |
US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DK0682027T3 (da) * | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
MX9709867A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
ES2167586T3 (es) | 1995-07-05 | 2002-05-16 | Du Pont | Pirimidinonas fungicidas. |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
CN1168138A (zh) | 1995-11-14 | 1997-12-17 | 法玛西雅厄普约翰公司 | 芳基和杂芳基嘌呤化合物 |
AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
JP2000515136A (ja) | 1996-07-13 | 2000-11-14 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物 |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
AU720429B2 (en) * | 1996-08-23 | 2000-06-01 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
AU4718997A (en) | 1996-11-27 | 1998-06-22 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
EP0972197A1 (en) * | 1997-03-24 | 2000-01-19 | PHARMACIA & UPJOHN COMPANY | Method for identifying inhibitors of jak2/cytokine receptor binding |
JP2002510687A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ |
AU4317399A (en) | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
PL198640B1 (pl) * | 1998-06-19 | 2008-07-31 | Pfizer Prod Inc | Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
IL141434A0 (en) | 1998-08-21 | 2002-03-10 | Parker Hughes Inst | Quinazoline derivatives |
EP1114053A1 (en) | 1998-09-18 | 2001-07-11 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
JP2003510327A (ja) * | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | 特定のアルキレンジアミンで置換された複素環 |
ATE380031T1 (de) | 1999-12-10 | 2007-12-15 | Pfizer Prod Inc | Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen |
HUP0301114A3 (en) * | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
ATE355275T1 (de) * | 2000-10-20 | 2006-03-15 | Eisai R&D Man Co Ltd | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
GT200200234A (es) * | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
PL378246A1 (pl) * | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Sposób leczenia odrzucania przeszczepu |
WO2004093812A2 (en) * | 2003-04-22 | 2004-11-04 | Irm Llc | Compounds that induce neuronal differentiation in embryonic stem cells |
AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
AU2004305317A1 (en) * | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection |
CA2548951A1 (en) * | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
CA2572331A1 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
WO2006017443A2 (en) * | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
-
2009
- 2009-08-10 NZ NZ605292A patent/NZ605292A/en unknown
- 2009-08-10 SI SI200930918T patent/SI2384326T1/sl unknown
- 2009-08-10 PT PT97868822T patent/PT2384326E/pt unknown
- 2009-08-10 CN CN200980132519.2A patent/CN102131812B/zh active Active
- 2009-08-10 ME MEP-2011-22A patent/ME01269B/me unknown
- 2009-08-10 DK DK09786882.2T patent/DK2384326T3/da active
- 2009-08-10 AU AU2009283844A patent/AU2009283844B2/en active Active
- 2009-08-10 RS RS20140332A patent/RS53382B/en unknown
- 2009-08-10 MX MX2011001904A patent/MX2011001904A/es active IP Right Grant
- 2009-08-10 KR KR1020117003834A patent/KR101335843B1/ko active Protection Beyond IP Right Term
- 2009-08-10 WO PCT/IB2009/053514 patent/WO2010020905A1/en active Application Filing
- 2009-08-10 PL PL09786882T patent/PL2384326T3/pl unknown
- 2009-08-10 EP EP09786882.2A patent/EP2384326B1/en active Active
- 2009-08-10 BR BRPI0917459-1A patent/BRPI0917459B1/pt active IP Right Grant
- 2009-08-10 ES ES09786882.2T patent/ES2467109T3/es active Active
- 2009-08-10 CA CA2733359A patent/CA2733359C/en active Active
- 2009-08-10 JP JP2011523467A patent/JP4884570B2/ja active Active
- 2009-08-10 RU RU2011106331/04A patent/RU2493157C2/ru not_active Application Discontinuation
- 2009-08-17 US US12/542,451 patent/US8133899B2/en active Active
- 2009-08-18 AR ARP090103164A patent/AR073073A1/es not_active Application Discontinuation
- 2009-08-19 UY UY0001032059A patent/UY32059A/es active IP Right Grant
-
2011
- 2011-02-18 CL CL2011000353A patent/CL2011000353A1/es unknown
- 2011-02-18 CO CO11019992A patent/CO6331437A2/es active IP Right Grant
- 2011-03-04 ZA ZA2011/01701A patent/ZA201101701B/en unknown
- 2011-03-21 EC EC2011010904A patent/ECSP11010904A/es unknown
-
2012
- 2012-01-13 HK HK12100393.9A patent/HK1160116A1/xx unknown
- 2012-01-30 US US13/360,963 patent/US8987283B2/en active Active
-
2014
- 2014-04-30 HR HRP20140395AT patent/HRP20140395T1/hr unknown
-
2015
- 2015-02-11 US US14/619,195 patent/US9161939B2/en active Active
- 2015-09-15 US US14/854,632 patent/US9271981B2/en active Active
-
2016
- 2016-10-04 AR ARP160103034A patent/AR106252A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011106331A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА | |
ES2583086T3 (es) | Pirazolopiridinas sustituidas con fluoroalquilo y su uso | |
ES2877050T3 (es) | Compuestos y composiciones como agonistas del receptor 7 de tipo toll | |
JP5432376B2 (ja) | 縮合イミダゾール類および例えばマラリアのような寄生虫症の処置のためのそれらを含む組成物 | |
EP3079700B1 (en) | Soluble guanylate cyclase activators | |
JP2021169520A (ja) | Prmt5阻害剤として使用するための新規な6−6二環式芳香環置換ヌクレオシド類似体 | |
AU667527B2 (en) | Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an S-phase or M-phase specific antineoplastic agent | |
JP2018523679A (ja) | Parp阻害剤としてのヘテロアリール誘導体 | |
JP2016510010A (ja) | トリフルオロメチル置換環縮合ピリミジンおよびその使用 | |
AU2008271114A1 (en) | Novel HIV reverse transcriptase inhibitors | |
TW201213332A (en) | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | |
JP2010525057A (ja) | Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 | |
JP2022541749A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
JP2018513832A (ja) | 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 | |
EP4006034A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
US20110223131A1 (en) | Antiviral compounds | |
CN111518077B (zh) | 一种新型抗肿瘤ido抑制剂的制备方法 | |
AU2005302519A1 (en) | Compounds and methods of use thereof | |
JP2013518036A5 (ru) | ||
SA520412290B1 (ar) | مركبات جديدة مثبطة للهدف الميكانيكي للراباميسين | |
WO2023278600A1 (en) | Small molecule inhibitors of kras g12d mutant | |
EP4121430A1 (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
JP5194105B2 (ja) | 1−シクロプロピル−6−フルオロ−7−(8−メトキシイミノ−2,6−ジアザ−スピロ[3.4]オクト−6−イル)−4−オキソ−1,4−ジヒドロ−[1,8]ナフチリジン−3−カルボン酸のアスパラギンサン酸塩、その製造方法、およびそれを含む抗菌用薬学組成物 | |
WO2010011959A1 (en) | Antiviral compounds | |
ES2519441T3 (es) | Compuestos para tratar la impotencia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130109 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20130219 |
|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150120 |
|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20151120 |
|
RZ4A | Other changes in the information about an invention | ||
PD4A | Correction of name of patent owner |